JP2025509976A5 - - Google Patents
Info
- Publication number
- JP2025509976A5 JP2025509976A5 JP2024556159A JP2024556159A JP2025509976A5 JP 2025509976 A5 JP2025509976 A5 JP 2025509976A5 JP 2024556159 A JP2024556159 A JP 2024556159A JP 2024556159 A JP2024556159 A JP 2024556159A JP 2025509976 A5 JP2025509976 A5 JP 2025509976A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- nucleotides
- pharmaceutical composition
- composition according
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022900727 | 2022-03-23 | ||
| AU2022900727A AU2022900727A0 (en) | 2022-03-23 | Methods of treating glaucoma | |
| PCT/AU2023/050213 WO2023178386A1 (en) | 2022-03-23 | 2023-03-23 | Methods of treating glaucoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509976A JP2025509976A (ja) | 2025-04-11 |
| JP2025509976A5 true JP2025509976A5 (https=) | 2026-03-31 |
Family
ID=88099395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556159A Pending JP2025509976A (ja) | 2022-03-23 | 2023-03-23 | 緑内障の処置方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250179490A1 (https=) |
| EP (1) | EP4496892A1 (https=) |
| JP (1) | JP2025509976A (https=) |
| KR (1) | KR20240165951A (https=) |
| CN (1) | CN119053704A (https=) |
| AU (1) | AU2023237229A1 (https=) |
| CA (1) | CA3246175A1 (https=) |
| IL (1) | IL315133A (https=) |
| WO (1) | WO2023178386A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| WO2024221049A1 (en) * | 2023-04-28 | 2024-10-31 | PYC Therapeutics Limited | Agents and method of treatment for optic conditions |
| WO2025240992A1 (en) * | 2024-05-24 | 2025-11-27 | PYC Therapeutics Limited | Agents for treatment of conditions associated with optic atrophy 1 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050244851A1 (en) * | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| US20180305689A1 (en) * | 2015-04-22 | 2018-10-25 | Mina Therapeutics Limited | Sarna compositions and methods of use |
| CN115867657A (zh) * | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| AU2021354152A1 (en) * | 2020-10-02 | 2023-06-01 | PYC Therapeutics Limited | Treatment of optic atrophy |
| JP7811941B2 (ja) * | 2020-10-08 | 2026-02-06 | フォンダツィオーネ・イスティテュート・イタリアーノ・ディ・テクノロジア | 機能性核酸分子 |
-
2023
- 2023-03-23 KR KR1020247031264A patent/KR20240165951A/ko active Pending
- 2023-03-23 CA CA3246175A patent/CA3246175A1/en active Pending
- 2023-03-23 WO PCT/AU2023/050213 patent/WO2023178386A1/en not_active Ceased
- 2023-03-23 IL IL315133A patent/IL315133A/en unknown
- 2023-03-23 AU AU2023237229A patent/AU2023237229A1/en active Pending
- 2023-03-23 US US18/844,484 patent/US20250179490A1/en active Pending
- 2023-03-23 JP JP2024556159A patent/JP2025509976A/ja active Pending
- 2023-03-23 EP EP23773367.0A patent/EP4496892A1/en active Pending
- 2023-03-23 CN CN202380028595.9A patent/CN119053704A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025509976A5 (https=) | ||
| KR102095699B1 (ko) | 트랜스티레틴（ＴＴＲ） 관련 질병을 치료하기 위한 ＲＮＡｉ 제제, 조성 및 그의 사용방법 | |
| ES2649817T3 (es) | Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á | |
| TW201639961A (zh) | 含類馬鈴薯儲藏蛋白磷脂酶域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法 | |
| TW201631156A (zh) | Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法 | |
| CN116064515A (zh) | 甲状腺素运载蛋白（TTR）iRNA组合物及其治疗或预防TTR相关疾病的使用方法 | |
| CA2163234A1 (en) | Inhibition of proliferation of vascular smooth muscle cell | |
| JP2022501057A (ja) | トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物及びＴＴＲ関連眼疾患を治療又は予防するためのその使用方法 | |
| JP2008514647A (ja) | 二本鎖リボ核酸によって炎症性疾患を治療する方法 | |
| AU2006311912A1 (en) | Peptide-dicer substrate RNA conjugates as delivery vehicles for siRNA | |
| US10933081B2 (en) | Myostatin iRNA compositions and methods of use thereof | |
| TW202411427A (zh) | 用於抑制細胞中agt表現之核酸 | |
| JP2024514880A (ja) | Ｐｎｐｌａ３発現を調節するための組成物及び方法 | |
| KR20250125967A (ko) | 진보된 rna 표적화 (arnatar) | |
| TW202400792A (zh) | 用於抑制ｍａｐｔ表現之組合物及方法 | |
| KR102701681B1 (ko) | 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물 | |
| US20230416743A1 (en) | Compositions and methods for inhibiting snca expression | |
| AU2024302527A1 (en) | Advanced rna targeting (arnatar) for angiotensinogen | |
| RU2024126206A (ru) | Способы лечения глаукомы | |
| RU2804776C2 (ru) | СРЕДСТВА ДЛЯ РНКи, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ТРАНСТИРЕТИНОМ (TTR) | |
| WO2026064538A2 (en) | Advanced rna targeting (arnatar) for inhbe | |
| TW202345873A (zh) | 調節ｓｃａｐ活性之組合物及方法 | |
| WO2022092279A1 (ja) | ｓｉＲＮＡ及び医薬組成物並びに予防及び／又は治療剤 | |
| WO2024255749A1 (zh) | 靶向血管紧张素原的核酸及其用途 | |
| HK40116803A (zh) | 靶向血管紧张素原的核酸及其用途 |